Skip to main content
Log in

Translational Therapeutics

Comment on “Redefining cancer research for therapeutic breakthroughs”

  • Correspondence
  • Published:
British Journal of Cancer Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Yuzhalin AE. Redefining cancer research for therapeutic breakthroughs. Br J Cancer. 2024;130:1078–82. https://doi.org/10.1038/s41416-024-02634-6.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Zang Y, Lee JJ. Adaptive clinical trial designs in oncology. Chin Clin Oncol. 2014;3:49. https://doi.org/10.3978/j.issn.2304-3865.2014.06.04.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Mullins CD, Vandigo J, Zheng Z, Wicks P. Patient-centeredness in the design of clinical trials. Value Health. 2014;17:471–5. https://doi.org/10.1016/j.jval.2014.02.012.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16:29. https://doi.org/10.1186/s12916-018-1017-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Mehrara E, Forssell-Aronsson E, Bernhardt P. Objective assessment of tumour response to therapy based on tumour growth kinetics. Br J Cancer. 2011;105:682–6. https://doi.org/10.1038/bjc.2011.276.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kim ES, Atlas J, Ison G, Ersek JL. Transforming Clinical Trial Eligibility Criteria to Reflect Practical Clinical Application. Am Soc Clin Oncol Educ Book. 2016;35:83–90. https://doi.org/10.1200/EDBK_155880.

    Article  CAS  PubMed  Google Scholar 

  7. Johnson K, Gomez A, Burton J, White D, Chakravarty A, Schmid A, et al. Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth. Eur J Cancer. 2019;109:196–203. https://doi.org/10.1016/j.ejca.2018.11.008.

    Article  PubMed  Google Scholar 

  8. Xie X, Li X, Yao W. A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors. Transl Cancer Res. 2021;10:1119–30. https://doi.org/10.21037/tcr-20-2547.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Tang M, Pearson SA, Simes RJ, Chua BH. Harnessing Real-World Evidence to Advance Cancer Research. Curr Oncol. 2023;30:1844–59. https://doi.org/10.3390/curroncol30020143.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Farah E, Kenney M, Kica A, Haddad P, Stewart DJ, Bradford JP. Beyond Participation: Evaluating the Role of Patients in Designing Oncology Clinical Trials. Curr Oncol. 2023;30:8310–27. https://doi.org/10.3390/curroncol30090603.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

All contributions to this article its from Dr. Prasad Cooray (single author).

Corresponding author

Correspondence to Prasad Cooray.

Ethics declarations

Competing interests

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cooray, P. Comment on “Redefining cancer research for therapeutic breakthroughs”. Br J Cancer (2024). https://doi.org/10.1038/s41416-024-02695-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41416-024-02695-7

  • Springer Nature Limited

Navigation